Literature DB >> 28428345

Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.

Lena Allweiss1, Tassilo Volz1, Katja Giersch1, Janine Kah1, Giuseppina Raffa2, Joerg Petersen3, Ansgar W Lohse1,4, Concetta Beninati5, Teresa Pollicino2, Stephan Urban4,6, Marc Lütgehetmann1,7, Maura Dandri1,4.   

Abstract

OBJECTIVE: The stability of the covalently closed circular DNA (cccDNA) in nuclei of non-dividing hepatocytes represents a key determinant of HBV persistence. Contrarily, studies with animal hepadnaviruses indicated that hepatocyte turnover can reduce cccDNA loads but knowledge on the proliferative capacity of HBV-infected primary human hepatocytes (PHHs) in vivo and the fate of cccDNA in dividing PHHs is still lacking. This study aimed to determine the impact of human hepatocyte division on cccDNA stability in vivo.
METHODS: PHH proliferation was triggered by serially transplanting hepatocytes from HBV-infected humanised mice into naïve recipients. Cell proliferation and virological changes were assessed by quantitative PCR, immunofluorescence and RNA in situ hybridisation. Viral integrations were analysed by gel separation and deep sequencing.
RESULTS: PHH proliferation strongly reduced all infection markers, including cccDNA (median 2.4 log/PHH). Remarkably, cell division appeared to cause cccDNA dilution among daughter cells and intrahepatic cccDNA loss. Nevertheless, HBV survived in sporadic non-proliferating human hepatocytes, so that virological markers rebounded as hepatocyte expansion relented. This was due to reinfection of quiescent PHHs since treatment with the entry inhibitor myrcludex-B or nucleoside analogues blocked viral spread and intrahepatic cccDNA accumulation. Viral integrations were detected both in donors and recipient mice but did not appear to contribute to antigen production.
CONCLUSIONS: We demonstrate that human hepatocyte division even without involvement of cytolytic mechanisms triggers substantial cccDNA loss. This process may be fundamental to resolve self-limiting acute infection and should be considered in future therapeutic interventions along with entry inhibition strategies. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  ANTIVIRAL THERAPY; BASIC SCIENCES; CHRONIC HEPATITIS; HEPATITIS B

Mesh:

Substances:

Year:  2017        PMID: 28428345     DOI: 10.1136/gutjnl-2016-312162

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  58 in total

1.  Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.

Authors:  Janine Kah; Sarene Koh; Tassilo Volz; Erica Ceccarello; Lena Allweiss; Marc Lütgehetmann; Antonio Bertoletti; Maura Dandri
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

2.  Smc5/6 Antagonism by HBx Is an Evolutionarily Conserved Function of Hepatitis B Virus Infection in Mammals.

Authors:  Fabien Abdul; Fabien Filleton; Laetitia Gerossier; Alexia Paturel; Janet Hall; Michel Strubin; Lucie Etienne
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

Review 3.  Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B.

Authors:  Xupeng Hong; Elena S Kim; Haitao Guo
Journal:  Hepatology       Date:  2017-11-06       Impact factor: 17.425

4.  Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA?

Authors:  Markus Cornberg; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-31       Impact factor: 46.802

5.  Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an In Vitro Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles.

Authors:  Thomas Tu; Magdalena A Budzinska; Florian W R Vondran; Nicholas A Shackel; Stephan Urban
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 6.  Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential.

Authors:  Yuchen Xia; Haitao Guo
Journal:  Antiviral Res       Date:  2020-05-22       Impact factor: 5.970

7.  T cell receptor grafting allows virological control of Hepatitis B virus infection.

Authors:  Karin Wisskirchen; Janine Kah; Antje Malo; Theresa Asen; Tassilo Volz; Lena Allweiss; Jochen M Wettengel; Marc Lütgehetmann; Stephan Urban; Tanja Bauer; Maura Dandri; Ulrike Protzer
Journal:  J Clin Invest       Date:  2019-04-30       Impact factor: 14.808

8.  Hepatitis B Virus Deregulates the Cell Cycle To Promote Viral Replication and a Premalignant Phenotype.

Authors:  Yuchen Xia; Xiaoming Cheng; Yao Li; Kristin Valdez; Weiping Chen; T Jake Liang
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

9.  A global scientific strategy to cure hepatitis B.

Authors:  Peter A Revill; Francis V Chisari; Joan M Block; Maura Dandri; Adam J Gehring; Haitao Guo; Jianming Hu; Anna Kramvis; Pietro Lampertico; Harry L A Janssen; Massimo Levrero; Wenhui Li; T Jake Liang; Seng-Gee Lim; Fengmin Lu; M Capucine Penicaud; John E Tavis; Robert Thimme; Fabien Zoulim
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-04-10

Review 10.  The evolution and clinical impact of hepatitis B virus genome diversity.

Authors:  Peter A Revill; Thomas Tu; Hans J Netter; Lilly K W Yuen; Stephen A Locarnini; Margaret Littlejohn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-28       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.